scholarly journals Letter to the Editor: “Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study”

2019 ◽  
Vol 104 (8) ◽  
pp. 3146-3147 ◽  
Author(s):  
Cheryl Rockman-Greenberg
Keyword(s):  
Young Children ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Asfotase Alfa ◽  
Letter To The Editor ◽  
Infants And Young Children

scholarly journals Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study

2019 ◽  
Vol 104 (7) ◽  
pp. 2735-2747 ◽  
Author(s):  
Christine E Hofmann ◽  
Paul Harmatz ◽  
Jerry Vockley ◽  
Wolfgang Högler ◽  
Hideki Nakayama ◽  
...  
Keyword(s):  
Young Children ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Asfotase Alfa ◽  
Infants And Young Children

scholarly journals Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial

2019 ◽  
Vol 7 (2) ◽  
pp. 93-105 ◽  
Author(s):  
Michael P Whyte ◽  
Jill H Simmons ◽  
Scott Moseley ◽  
Kenji P Fujita ◽  
Nicholas Bishop ◽  
...  
Keyword(s):  
Young Children ◽  
Phase 2 ◽  
Open Label ◽  
Asfotase Alfa ◽  
Open Label Phase ◽  
Extension Trial ◽  
Infants And Young Children

ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E–mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS2604-TPS2604 ◽  
Author(s):  
Vivek Subbiah ◽  
Yung-Jue Bang ◽  
Ulrik Niels Lassen ◽  
Zev A. Wainberg ◽  
Jean-Charles Soria ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Braf V600e ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Rare Cancers
Sign in / Sign up

Export Citation Format

Share Document